MedPacto (235980) Fundamentals 2026 — Revenue Analysis | SniperIQ
MedPacto (235980) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩88.3B, trading at ₩2575.00 on the KOE. This SniperIQ fundamentals page covers MedPacto's valuation, profitability (net margin -276.0%), revenue (₩3.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is MedPacto's market cap?
MedPacto (235980) has a market capitalization of approximately ₩88.3B, trading at ₩2575.00 on the KOE. Market cap moves with the live share price.
What is MedPacto's P/E ratio?
MedPacto's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 2.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is MedPacto?
MedPacto runs a net profit margin of -276.0%, a gross margin of -0.1%, and an operating margin of -300.5%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does MedPacto generate?
MedPacto reported revenue of ₩3.9B for fiscal year 2025, with net income of -₩12.8B and earnings per share (EPS) of -373.92. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does MedPacto pay a dividend?
MedPacto does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is MedPacto financially healthy?
MedPacto carries a debt-to-equity ratio of 0.04x and a current ratio of 26.54x, with a market beta of 0.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is MedPacto a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For MedPacto (235980) the key facts are: market cap ₩88.3B, revenue ₩3.9B, 52-week range 2545-8650. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track MedPacto's full fundamentals live
Get MedPacto's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.